CN107551269A - 周围神经的IgG刺激髓鞘再生 - Google Patents

周围神经的IgG刺激髓鞘再生 Download PDF

Info

Publication number
CN107551269A
CN107551269A CN201710896364.6A CN201710896364A CN107551269A CN 107551269 A CN107551269 A CN 107551269A CN 201710896364 A CN201710896364 A CN 201710896364A CN 107551269 A CN107551269 A CN 107551269A
Authority
CN
China
Prior art keywords
polyclonal igg
mammal
peripheral neuropathy
cell
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710896364.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·屈瑞
N·策克瓦
H-P·哈尔图
C·赫尔曼
M·B·赖佩特
H-P·施瓦茨
H·欧利希
S·邦克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Hundred Deep LLC
Hundred Deep Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hundred Deep LLC, Hundred Deep Co filed Critical Hundred Deep LLC
Publication of CN107551269A publication Critical patent/CN107551269A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CN201710896364.6A 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生 Pending CN107551269A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
US61/605,117 2012-02-29
CN201380021280.8A CN104302666A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380021280.8A Division CN104302666A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生

Publications (1)

Publication Number Publication Date
CN107551269A true CN107551269A (zh) 2018-01-09

Family

ID=47884569

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201710896364.6A Pending CN107551269A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生
CN201380021280.8A Pending CN104302666A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生
CN201910611688.XA Pending CN110343171A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生
CN201910008205.7A Pending CN109966488A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201380021280.8A Pending CN104302666A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生
CN201910611688.XA Pending CN110343171A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生
CN201910008205.7A Pending CN109966488A (zh) 2012-02-29 2013-02-28 周围神经的IgG刺激髓鞘再生

Country Status (21)

Country Link
US (5) US8986670B2 (enExample)
EP (2) EP2820042B1 (enExample)
JP (3) JP6335800B2 (enExample)
KR (3) KR20200126005A (enExample)
CN (4) CN107551269A (enExample)
AR (2) AR090211A1 (enExample)
AU (3) AU2013203088B2 (enExample)
BR (1) BR112014021240A2 (enExample)
DK (2) DK2820042T3 (enExample)
EA (2) EA032000B1 (enExample)
ES (2) ES2755056T3 (enExample)
FI (1) FI3590960T3 (enExample)
HK (1) HK1248534A1 (enExample)
IL (3) IL277103B2 (enExample)
MX (2) MX369444B (enExample)
NZ (1) NZ629867A (enExample)
PL (2) PL3590960T3 (enExample)
PT (2) PT3590960T (enExample)
SG (1) SG11201405302WA (enExample)
TW (3) TW201838654A (enExample)
WO (1) WO2013130826A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3473407D1 (en) 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1992003536A1 (en) * 1990-08-15 1992-03-05 University Of Miami And Its School Of Medicine Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EP2287191B1 (en) * 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
MXPA06008435A (es) * 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
NZ578816A (en) * 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Also Published As

Publication number Publication date
MX2019012496A (es) 2020-01-20
AU2016201137A1 (en) 2016-03-10
US10494418B2 (en) 2019-12-03
TW201400502A (zh) 2014-01-01
HK1206035A1 (en) 2015-12-31
PL2820042T3 (pl) 2020-03-31
EP2820042A2 (en) 2015-01-07
NZ629867A (en) 2016-09-30
EA201892521A1 (ru) 2019-07-31
AU2016201137B2 (en) 2017-10-12
IL234303B (en) 2020-09-30
IL277103A (en) 2020-10-29
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
TWI700297B (zh) 2020-08-01
JP2020059705A (ja) 2020-04-16
CN109966488A (zh) 2019-07-05
CN104302666A (zh) 2015-01-21
SG11201405302WA (en) 2014-09-26
PL3590960T3 (pl) 2023-07-17
IL277103B1 (en) 2025-03-01
CN110343171A (zh) 2019-10-18
US20180291087A1 (en) 2018-10-11
ES2943585T3 (es) 2023-06-14
PT3590960T (pt) 2023-04-18
AU2018200026A1 (en) 2018-01-25
AR117207A2 (es) 2021-07-21
PT2820042T (pt) 2019-10-31
MX369444B (es) 2019-11-08
AU2013203088B2 (en) 2015-12-03
TWI632158B (zh) 2018-08-11
JP2015508824A (ja) 2015-03-23
EP3590960A1 (en) 2020-01-08
EA032000B1 (ru) 2019-03-29
KR20200126005A (ko) 2020-11-05
FI3590960T3 (fi) 2023-04-25
DK2820042T3 (da) 2019-10-28
WO2013130826A3 (en) 2013-12-05
US8986670B2 (en) 2015-03-24
EA201400966A1 (ru) 2014-12-30
AR090211A1 (es) 2014-10-29
AU2018200026B2 (en) 2019-12-05
KR102673154B1 (ko) 2024-06-05
TW201736398A (zh) 2017-10-16
AU2013203088A1 (en) 2013-09-19
IL274512A (en) 2020-06-30
US9834593B2 (en) 2017-12-05
ES2755056T3 (es) 2020-04-21
IL277103B2 (en) 2025-07-01
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
HK1248534A1 (zh) 2018-10-19
US20200216518A1 (en) 2020-07-09
KR20140134690A (ko) 2014-11-24
US20150232536A1 (en) 2015-08-20
US20130224150A1 (en) 2013-08-29
IL274512B2 (en) 2024-07-01
KR20220045087A (ko) 2022-04-12
TW201838654A (zh) 2018-11-01
EP3590960B1 (en) 2023-03-29
MX2014010387A (es) 2015-09-25
US20210300997A1 (en) 2021-09-30
IL274512B1 (en) 2024-03-01
JP6335800B2 (ja) 2018-05-30
BR112014021240A2 (pt) 2018-09-18
JP6979990B2 (ja) 2021-12-15
JP2018030856A (ja) 2018-03-01
JP6637934B2 (ja) 2020-01-29

Similar Documents

Publication Publication Date Title
US20210300997A1 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
AU2003285864B2 (en) Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
KR102959210B1 (ko) 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
HK1206035B (en) Igg stimulated remyelination of peripheral nerves
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248534

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210630

Address after: Osaka

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Illinois, USA

Applicant before: Baishen Co.

Applicant before: BAXALTA GmbH